dc.contributor.author | Gyawali, R. | |
dc.contributor.author | Baral, A. | |
dc.contributor.author | Upreti, D. | |
dc.contributor.author | Yadav, C.B. | |
dc.contributor.author | Gupta, A.K. | |
dc.contributor.author | Chandradasa, M. | |
dc.contributor.author | Shoib, S. | |
dc.date.accessioned | 2022-03-25T07:40:52Z | |
dc.date.available | 2022-03-25T07:40:52Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Archives of Women's Mental Health.2022;25(3):671-674.[Epub 2022 Mar 14] | en_US |
dc.identifier.issn | 1434-1816 | |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/24550 | |
dc.description | Indexed in MEDLINE. | en_US |
dc.description.abstract | Olanzapine is widely used during pregnancy to manage mood and psychotic disorders with overall beneficial effects. There have been past reports of olanzapine exposure during early pregnancy and clubfoot in two newborns from India and Israel. We report a woman in Nepal diagnosed with schizophrenia and treated with olanzapine throughout the pregnancy delivering a baby boy with congenital talipes equinovarus deformity. Like in many other low-income settings, pregnancy was unplanned, and pre-conception counselling was not done. Research in mice has revealed the negative effects of olanzapine on bone development. Further reports would strengthen this potential association between exposure to olanzapine in the first trimester and the occurrence of clubfoot in the baby. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer,New York | en_US |
dc.subject | Antipsychotic Agents | en_US |
dc.subject | Clubfoot | en_US |
dc.title | Novel report on congenital talipes equinovarus (CTEV) following olanzapine exposure during pregnancy: case report and short review. | en_US |
dc.type | Article | en_US |
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |